HK1209111A1 - 醌系化合物及其用於癌症治療的用途 - Google Patents
醌系化合物及其用於癌症治療的用途Info
- Publication number
- HK1209111A1 HK1209111A1 HK15109758.6A HK15109758A HK1209111A1 HK 1209111 A1 HK1209111 A1 HK 1209111A1 HK 15109758 A HK15109758 A HK 15109758A HK 1209111 A1 HK1209111 A1 HK 1209111A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- treatment
- quinone compounds
- quinone
- compounds
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000004053 quinones Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
- C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1213486.2A GB201213486D0 (en) | 2012-07-30 | 2012-07-30 | Quinone compounds and their uses for the treatment of cancer |
| PCT/EP2013/065968 WO2014020012A1 (en) | 2012-07-30 | 2013-07-30 | Quinone compounds and their uses for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1209111A1 true HK1209111A1 (zh) | 2016-03-24 |
Family
ID=46881339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15109758.6A HK1209111A1 (zh) | 2012-07-30 | 2015-10-06 | 醌系化合物及其用於癌症治療的用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9266829B2 (zh) |
| EP (1) | EP2882743B1 (zh) |
| JP (1) | JP6317742B2 (zh) |
| KR (1) | KR102142164B1 (zh) |
| CN (1) | CN104583200B (zh) |
| AU (1) | AU2013298653B2 (zh) |
| BR (1) | BR112015001837B1 (zh) |
| CA (1) | CA2880021C (zh) |
| DK (1) | DK2882743T3 (zh) |
| ES (1) | ES2662917T3 (zh) |
| GB (2) | GB201213486D0 (zh) |
| HK (1) | HK1209111A1 (zh) |
| IN (1) | IN2015DN01223A (zh) |
| MX (1) | MX361650B (zh) |
| NO (1) | NO2882743T3 (zh) |
| RU (1) | RU2688675C2 (zh) |
| WO (1) | WO2014020012A1 (zh) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156744A (en) * | 1998-03-19 | 2000-12-05 | Cancer Research Campaign Tech (London) | DT-diaphorase directed anti-tumor agents |
| KR20070032795A (ko) * | 2004-06-21 | 2007-03-22 | 허치슨 메디파르마 엔터프라이즈 리미티드 | 항암 화학요법 |
| EP2134322B1 (en) * | 2007-03-13 | 2019-02-20 | Spectrum Pharmaceuticals, Inc. | Intravesical apaziquone administration following transurethral resection for treating bladder cancer |
-
2012
- 2012-07-30 GB GBGB1213486.2A patent/GB201213486D0/en not_active Ceased
-
2013
- 2013-07-30 WO PCT/EP2013/065968 patent/WO2014020012A1/en active Application Filing
- 2013-07-30 IN IN1223DEN2015 patent/IN2015DN01223A/en unknown
- 2013-07-30 KR KR1020157002128A patent/KR102142164B1/ko active IP Right Grant
- 2013-07-30 JP JP2015524762A patent/JP6317742B2/ja not_active Expired - Fee Related
- 2013-07-30 BR BR112015001837-8A patent/BR112015001837B1/pt not_active IP Right Cessation
- 2013-07-30 EP EP13742640.9A patent/EP2882743B1/en not_active Not-in-force
- 2013-07-30 NO NO13742640A patent/NO2882743T3/no unknown
- 2013-07-30 CA CA2880021A patent/CA2880021C/en not_active Expired - Fee Related
- 2013-07-30 DK DK13742640.9T patent/DK2882743T3/en active
- 2013-07-30 MX MX2015000969A patent/MX361650B/es active IP Right Grant
- 2013-07-30 ES ES13742640.9T patent/ES2662917T3/es active Active
- 2013-07-30 GB GB1422799.5A patent/GB2519004B/en not_active Expired - Fee Related
- 2013-07-30 RU RU2015105036A patent/RU2688675C2/ru not_active IP Right Cessation
- 2013-07-30 AU AU2013298653A patent/AU2013298653B2/en not_active Ceased
- 2013-07-30 CN CN201380040388.1A patent/CN104583200B/zh not_active Expired - Fee Related
- 2013-07-30 US US14/418,394 patent/US9266829B2/en not_active Expired - Fee Related
-
2015
- 2015-10-06 HK HK15109758.6A patent/HK1209111A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN104583200A (zh) | 2015-04-29 |
| GB2519004A (en) | 2015-04-08 |
| WO2014020012A1 (en) | 2014-02-06 |
| JP2015524815A (ja) | 2015-08-27 |
| AU2013298653A1 (en) | 2015-02-19 |
| ES2662917T3 (es) | 2018-04-10 |
| MX361650B (es) | 2018-12-13 |
| KR20150036215A (ko) | 2015-04-07 |
| EP2882743B1 (en) | 2017-12-13 |
| AU2013298653B2 (en) | 2017-10-19 |
| CA2880021C (en) | 2020-01-14 |
| IN2015DN01223A (zh) | 2015-06-26 |
| JP6317742B2 (ja) | 2018-04-25 |
| GB2519004B (en) | 2016-03-30 |
| DK2882743T3 (en) | 2018-03-12 |
| US20150210639A1 (en) | 2015-07-30 |
| BR112015001837B1 (pt) | 2021-11-16 |
| US9266829B2 (en) | 2016-02-23 |
| RU2688675C2 (ru) | 2019-05-22 |
| CA2880021A1 (en) | 2014-02-06 |
| NO2882743T3 (zh) | 2018-05-12 |
| KR102142164B1 (ko) | 2020-08-06 |
| CN104583200B (zh) | 2017-07-25 |
| BR112015001837A2 (pt) | 2017-07-04 |
| EP2882743A1 (en) | 2015-06-17 |
| GB201213486D0 (en) | 2012-09-12 |
| RU2015105036A (ru) | 2016-09-20 |
| MX2015000969A (es) | 2015-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190046T1 (hr) | Kombinirana terapija za liječenje raka | |
| IL261659A (en) | Brain cancer treatment | |
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| EP2920308A4 (en) | TREATMENT OF CANCER | |
| IL263781A (en) | Combined treatment of ovarian cancer | |
| EP2830633A4 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
| HK1214128A1 (zh) | 癌症的治療 | |
| HK1205254A1 (zh) | 治療癌症的方法 | |
| GB201217892D0 (en) | Treatment of cancer | |
| HK1204956A1 (zh) | 癌症治療 | |
| SI2892925T1 (sl) | Kombinacijsko zdravljenje raka | |
| DK2872176T3 (en) | Cancer treatment | |
| IL236321A0 (en) | Combined treatment for cancer and immunosuppression | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| GB201217890D0 (en) | Treatment of cancer | |
| HK1209111A1 (zh) | 醌系化合物及其用於癌症治療的用途 | |
| HK1200094A1 (zh) | 免疫調節劑用於治療癌症的用途 | |
| IL233495A0 (en) | Combination for cancer treatment | |
| GB201222949D0 (en) | Combination Treatment of Cancer | |
| GB201222950D0 (en) | Combination treatment of cancer | |
| GB201208296D0 (en) | Treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200730 |